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Fluconazole is a first-line antifungal agent for the treatment and prophylaxis of invasive candidiasis in pediatric patients. Pediat-
ric patients are at risk of suboptimal drug exposure, due to developmental changes in gastrointestinal and renal function, meta-
bolic capacity, and volume of distribution. Therapeutic drug monitoring (TDM) can therefore be useful to prevent underexpo-
sure of fluconazole in children and infants. Children, however, often fear needles and can have difficult vascular access. The
purpose of this study was to develop and clinically validate a method of analysis to determine fluconazole in oral fluid in pediat-
ric patients. Twenty-one paired serum and oral fluid samples were obtained from 19 patients and were analyzed using a validated
liquid chromatography-tandemmass spectrometry (LC–MS-MS) method after cross-validation between serum and oral fluid.
The results were within accepted ranges for accuracy and precision, and samples were stable at room temperature for at least 17
days. A Pearson correlation test for the fluconazole concentrations in serum and oral fluid showed a correlation coefficient of
0.960 (P< 0.01). The mean oral fluid-to-serum concentration ratio was 0.99 (95% confidence interval [CI], 0.88 to 1.10) with
Bland-Altman analysis. In conclusion, an oral fluid method of analysis was successfully developed and clinically validated for
fluconazole in pediatric patients and can be a noninvasive, painless alternative to perform TDM of fluconazole when blood sam-
pling is not possible or desirable. When patients receive prolonged courses of antifungal treatment and use fluconazole at home,
this method of analysis can extend the possibilities of TDM for patients at home.
Fluconazole was introduced in 1990 and is still a first-lineantifungal agent for the treatment and prophylaxis of inva-
sive candidiasis in children and infants (1, 2). The bioavailabil-
ity of orally administered fluconazole is over 90%, and flucona-
zole has excellent penetration in tissue and body fluids (3, 4). The
pharmacokinetic/pharmacodynamic parameter that best predicts
the outcome of the fluconazole treatment is the area under the
concentration-time curve over 24 h in steady state divided by the
MIC (AUC/MIC) (5, 6). To ensure an AUC/MIC of 50, which
corresponds to a favorable outcome, an AUC of400 mg · h/liter
is required for Candida species with a MIC breakpoint of8 mg/
liter (7–10). Routine therapeutic drug monitoring (TDM) of flu-
conazole is currently not advised due to its high bioavailability,
linear dose-concentration relationship, and good safety profile (1,
11, 12). However, children and infants are at risk of suboptimal
drug exposure, due to developmental changes in the gastrointes-
tinal and renal function, metabolic capacity, and volume of distri-
bution (13). A previous study showed that the serum fluconazole
concentration was correlated with the age, weight, and renal func-
tion of critically ill pediatric patients and that the fluconazole ex-
posurewas not sufficient in pediatric cancer patients (14). TDMof
fluconazole can therefore be useful to prevent possible underex-
posure in critically ill pediatric patients (14, 15). Since obtaining a
blood sample from children is often more complicated than for
adults and children often fear needles, oral fluid sampling can be a
noninvasive, painless alternative to plasma or serum (16). Previ-
ous studies showed a mean ratio of the saliva drug concentration
to the plasma drug concentration of approximately 1 for flucona-
zole in healthy volunteers (3, 17, 18). However, in another study,
a saliva-to-plasma concentration ratio of 0.4 was found (19). A
median saliva-to-plasma ratio of 1.1 to 1.3 was seen in adult pa-
tients with HIV or AIDS (20, 21) and a mean ratio of 1.4 in adult
cancer patients who underwent radiotherapy (22). The correla-
tion between fluconazole in oral fluid and in plasma or serum has
not yet been studied in children. The purpose of this study was to
develop and clinically validate a method of analysis of fluconazole
in oral fluid in hospitalized children with an (invasive) Candida
infection and to evaluate the fluconazole exposure in these chil-
dren.
MATERIALS AND METHODS
Study design. This prospective observational study was conducted in the
150-bed pediatric department of the University Medical Center Gro-
ningen, Groningen, The Netherlands, from July 2007 to March 2014.
Patients were eligible for inclusion if the following criteria were met: (i)
age, 0 to 18 years; (ii) admission to a pediatric ward or pediatric/neonatal
intensive care unit (ICU); (iii) oral or intravenous treatment with flu-
conazole; and (iv) scheduled routine TDM of fluconazole in serum. Chil-
dren from whom it was impossible to get oral fluid or who had serious
mucositis of their oral cavity or oral thrush were excluded from the study.
The study protocol was approved by the local medical ethics committee
(institutional review board protocol no. 2007.198). For patients less than
12 years of age, written informed consent was given by the parents, and for
patients over 12 years of age, the patient and parents were both asked to
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give informed consent. The study population was also included in a ret-
rospective study of fluconazole exposure by van der Elst et al. (14).
Routine serum and oral fluid trough samples were obtained pairwise
before administration of fluconazole. Fluconazole samples were eligible
for evaluation when obtained at steady state, which is after 2 days when a
loading dose has been given or after 5 dayswithout a loading dose (10, 23).
Serumwas obtained by centrifuging the blood samples, and the serumwas
directly analyzed or stored at 20°C until analysis. Only the unbound
fraction of fluconazole is present in oral fluid. Since the protein binding of
fluconazole is only 11 to 12% (18, 20), the total fluconazole concentration
was determined in serum. Oral fluid samples were obtained by chewing/
sucking for 1 min on a small cotton roll (Salivette, without preparation;
Sarstedt, Leicester, United Kingdom). If the patient was unable to chew,
the oral fluid samples were obtained through suction of the oral fluid with
a routine suction device. Oral fluid samples were directly centrifuged and
stored at 20°C until analysis. Demographic and clinical data were col-
lected through review of the medical records and included age, sex,
weight, renal function (serum urea and serum creatinine concentration),
underlying condition, stay in an ICU, and the Candida species. Medical
data were collected on the fluconazole dose (mg/kg of body weight/day)
and route of administration, fluconazole trough concentration, and du-
ration of treatment.
Oral fluidmethod validation. Fluconazole serum and oral fluid sam-
ples were analyzed using a previously validated liquid chromatography-
tandem mass spectrometry (LC–MS-MS) method (24). The analytical
method was validated in accordance with the Guidance for Industry, Bio-
analytical Method Validation of the Food and Drug Administration (25).
Cross-validation between serum and oral fluid was performed by com-
paring calibration samples of pooled serum and pooled oral fluid. The
lower limit of quantification (LOQ)was 0.5g/ml for both the serum and
oral fluid assays. The linearity of the standard curve was assessed with 1/x2
weighting over a concentration range of 0.5 to 50.0 g/ml. Accuracy and
precision were evaluated for quality control samples at concentrations of
0.5, 1.0, 2.5, 5.0, 10.0, 20.0, 40.0, and 50.0g/ml in triplicate. Stability was
assessed by storing oral fluid samples with fluconazole concentrations of
1.0 g/ml (low), 20.0 g/ml (medium), and 40.0 g/ml (high) at room
temperature (20°C) for 1, 3, 5, and 17 days. For the determination of the
recovery of fluconazole from the cotton rolls, 1.5 ml spiked oral fluid at
low, medium, and high concentrations was applied to the Salivette. After-
wards, the Salivettes were centrifuged, and the extracts were compared to
blank oral fluid subsequently spiked at low,medium, and high concentra-
tions. The recovery was determined immediately after preparation of the
Salivettes and after storing the Salivettes for 2 and 6 days at room temper-
ature (20°C). The analysis was clinically validated by comparing the flu-
conazole concentrations in paired serum and oral fluid samples from
patients. Furthermore, the percentage of patients with a fluconazole
trough concentration of11 g/ml (10, 14, 23) was determined.
Statistical analysis. In the analytical method validation, bias was de-
fined as the difference between the analytical result and the nominal con-
centration, expressed as a percentage. The oral fluid analysis was validated
by comparing the serum fluconazole concentration with the concentra-
tion of fluconazole in oral fluid using Passing-Bablok regression and
Bland-Altman analysis (with Analyze-it 2.20 software). Furthermore, a
Pearson correlation coefficient was calculated to determine the correla-
tion between the concentrations in serum and oral fluid. Additionally, a
leave-one-out cross-validation was performed to validate the predictive
performance of a linear regression model used to predict serum concen-
trations based on oral fluid concentrations. In this model, the serum flu-
conazole concentration was set as the dependent variable and the oral
fluid fluconazole concentration as the independent variable. The model
was refitted n times (with n the total number of observations) while leav-
ing out a single observation t, so that a prediction could be derived for the
left-out observation based on all other observations. The error for obser-
vation t was then defined as the difference between the observed and
predicted serum fluconazole concentrations, as follows: Yt
obs  Yt
pred. In
order to determine the performance of the linear regression model, the
root mean square error (RMSE) was calculated using the following equa-
tion: RMSEt1n Ytobs Ytpred2n .
In regard to patients, values are expressed as medians with interquar-
tile range (IQR) for continuous variables and as percentages of the group
from which they were derived for categorical variables. A Spearman cor-
relation coefficient was calculated to determine correlations between two
continuous variables. To compare two groups, the Mann-Whitney U test
was used. Statistical analyses were performed using SPSS for Windows,
version 20.0 (IBM SPSS, Chicago, IL). A P value of0.05 was considered
statistically significant.
RESULTS
A total of 19 patients were included in the study, and theirmedical
records were reviewed. The mean age of the patients was 4.6 years
(range, 22 days to 16 years), and 9 patients (47.4%)weremale. The
patients’ characteristics are summarized in Table 1. The causative
pathogen was Candida albicans in 16 patients (84.2%), C. parap-
silosis in 1 patient (5.3%), C. krusei in 1 patient (5.3%), and not
specified in 1 patient (5.3%). Themedian fluconazole dosewas 9.4
mg/kg/day (IQR, 6.4 to 10.4mg/kg/day), and themedian duration
of the fluconazole treatment was 31 days (IQR, 18 to 61 days).
Thirteen patients (68.4%) received fluconazole intravenously,
and 6 patients (31.6%) received oral treatment. The fluconazole
serum trough concentrations ranged from 2.8 to 37.5 g/ml.
Analytical method validation. The serum and oral fluid
analytical method showed good linearity over the fluconazole
concentration range. The regression equations and correlation co-
efficients were as follows: 0.00195 0.0274 response and r2
0.998 for serum and 0.000461  0.0265  response and r2 
0.997 for oral fluid. The mean measured concentrations were
between 93.8% and 102.7% of the nominal concentration for se-
rumandbetween 96.6%and 107.4% for oral fluid. The calibration
curveswere analyzed in triplicate, with the coefficients of variation
between 1.2%and 5.9% for serumandbetween 1.4%and 5.4% for
oral fluid, well within the required limit of 15% for the whole
concentration range. Serum samples were stable at room temper-
ature (20°C) for 7 days, with a bias of 2.3% for the low, 7.6% for





Gender (male) 9 (47.4)
Age
0–1 mo 2 (10.5)
1–24 mo 8 (42.1)
2–12 yr 6 (31.6)
12–18 yr 3 (15.8)
Underlying condition





Stay in intensive care unit 11 (57.9)
a Other: 1 patient was diagnosed with cardiac and respiratory insufficiency, 1 patient
with liver failure, and 1 patient with spina bifida.
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themedium, and 5.6% for the high concentrations (24). Oral fluid
samples were stable at room temperature (20°C) for 1, 3, 5, and 17
days, with a bias of 3.5% to 12.9% for the low, 2.8% to 6.1% for the
medium, and 0.6% to 5.7% for the high concentrations. The
recovery of the fluconazole extraction from the cotton rolls was
between 93.5% and 97.8% for the freshly prepared Salivettes and
between 97.3% and 104.8% after storing the Salivettes at room
temperature (20°C) for 2 and 6 days and was well within the re-
quired limit of15%.
Clinical validation. Twenty-one paired serum and oral fluid
samples from 19 patients were included in the clinical validation
of the oral fluid analysis. A Pearson correlation test showed a cor-
relation coefficient of 0.960 (P  0.01) for the fluconazole con-
centrations in serum and oral fluid. The unadjustedmedian of the
oral fluid-to-serum ratio was 1.00 (range, 0.59 to 1.46). Passing-
Bablok regression between the serum and oral fluid drug concen-
trations showed a proportional bias of 0.87 (95% confidence in-
terval [CI], 0.69 to 0.98) and a constant bias of 1.19 (95% CI, 0.44
to 2.92) (Fig. 1).With Bland-Altman analysis, themean oral fluid-
to-serumdrug concentration ratio versus themean concentration
in oral fluid and serum was 0.99 (95% CI, 0.88 to 1.10). Twenty
out of 21 values were within the limits of agreement of 95% (Fig.
2). Using a leave-one-out cross-validation analysis, the standard
deviation of the error in the predictive linear regressionmodel was
found to be 3.1 g/ml. The oral fluid-to-serum drug concentra-
tion ratio did not significantly differ in patients receiving oral
treatment versus intravenous treatment (P  0.791). No signifi-
cant correlation was found between the oral fluid-to-serum drug
concentration ratio and the age (P 0.316) or weight (P 0.266)
of the patient, the renal function (P 0.743 for urea andP 0.186
for the creatinine concentration), or the fluconazole dose (P 
0.636). Ten patients (52.6%) had a serum fluconazole concentra-
tion of11 g/ml, which is considered representative of an AUC
of400 mg · h/liter (10, 14, 23).
DISCUSSION
An oral fluid analysis for fluconazole was developed and clinically
validated in pediatric patients. The fluconazole concentration in
oral fluid was in good agreement with the serum fluconazole con-
centration. The mean oral fluid-to-serum drug concentration ra-
tio was 1, which corresponds to the ratio of 1 reported in the
summary of product characteristics of fluconazole (18) and in
studies in healthy volunteers (3, 17). Fluconazole has a lowprotein
binding of 11% to 12% and is largely nonionized under physio-
logical conditions, which makes fluconazole easily penetrate in
oral fluid (18, 20). In the high-concentration area (30 g/ml),
the concentration in oral fluidwas lower than the concentration in
serum, which possibly indicates saturation of the amount of flu-
conazole in the oral fluid. It is possible that fluconazole is excreted
in oral fluid, not only by passive diffusion, but also by an active
transport mechanism (20). However, there were only 2 patients
with a serum trough concentration of 30 g/ml, and previous
reports studied fluconazole trough concentrations only up to 10
g/ml (17, 19, 20, 22, 26).
FIG 1 Scatter plot (n 21)with Passing-Bablok regression between serumand oral fluid concentrations. The regression line of fluconazole is presented as a solid
line and has a slope of 0.87 (95% CI, 0.69 to 0.98) and an intercept of 1.19 (95% CI, 0.44 to 2.92).
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The overall bias between the fluconazole concentrations in oral
fluid and serum foundwith Bland-Altman analysis was low.How-
ever, in the low-concentration area, a larger bias was seen in the
oral fluid-to-serum ratio with Bland-Altman analysis. Further-
more, the standard deviation of the error in the predictive linear
regressionmodel was 3.1g/ml.When increasing the fluconazole
dose in case of underexposure based on the oral fluid drug con-
centration, this standard deviation must be taken into account,
especially when the measured concentration is ranged around the
target concentration. A slightly higher fluconazole trough concen-
tration can be pursued to ensure the exposure is adequate. This
higher fluconazole concentration is not likely to cause adverse
drug reactions, since fluconazole has a good safety profile and is
well tolerated in pediatric patients at higher doses (12). In case the
MIC for theCandida species is known, the fluconazole dose can be
adjusted to achieve the required exposure and to prevent unnec-
essary dose increase. TDM of fluconazole revealed a fluconazole
trough concentration of 11 g/ml in 52.6% of the pediatric
patients. Hence, TDM of fluconazole can be useful to detect pos-
sible underexposure in children and infants.
In our hospital, only trough concentrations of fluconazole
were measured and included in the clinical validation. The oral
fluid-to-serum concentration ratio of 1 that was found in this
study can therefore be applied only to fluconazole trough concen-
trations. A trough concentration is probably most convenient to
obtain and will give no drug contamination when fluconazole is
administered orally. Furthermore, oral fluid was collected by
chewing/sucking on a small cotton roll (Salivette) or by a routine
suction device when the patient was not able to chew. Collection
devices other than the Salivette have not been clinically validated
in our study. Research has shown that Salivette collection devices
achieve good recovery for most drugs, and they were found to be
very practical and convenient for the user (27). In contrast with
full-term infants, the collection of oral fluid from premature
neonates was difficult, since these patients produce very little oral
fluid. Oral fluid sampling is therefore not suitable for premature
neonates. In some other cases, blood sampling may also be pre-
ferred over oral fluid sampling, for example, when other labora-
tory tests are ordered along with the fluconazole measurement.
Furthermore, in patients with severemucositis or other damage to
or inflammation of the oral mucosa/salivary glands and in pa-
tients where oral fluid production is reduced (e.g., when treated
with anticholinergic comedication), blood sampling is preferred
(16).
Based on the results of our study, TDM of fluconazole in oral
fluid can be a noninvasive, painless alternative to serum in chil-
dren who fear needles or who have difficult vascular access. Oral
fluid sampling is preferred over blood sampling by themajority of
patients and their parents (16). Besides, oral fluid sampling can
reduce costs due to the lower level of training of personnel, less
time needed for oral fluid sampling, and lower costs of materials
used for oral fluid sampling (16). When patients receive pro-
longed courses of antifungal treatment and use fluconazole at
home, oral fluid sampling by the parents or the patient can extend
the possibilities of TDM for patients at home. Samples do not have
to be obtained solely during office hours and can be shipped by
FIG 2 Bland-Altman plot of the oral fluid-to-serum drug concentration ratio versus the mean concentration in oral fluid and serum. The bias is presented as a
solid line, and the 95% limits of agreement are presented as dashed lines. The mean bias is 0.99 (95% CI, 0.88 to 1.10), and the lower and upper 95% limits of
agreement are 0.53 (95% CI, 0.34 to 0.72) and 1.45 (95% CI, 1.27 to 1.64), respectively.
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mail, thereby avoiding trips to the hospital, and the biohazard risk
when shipping oral fluid samples is low. Furthermore, the physi-
cian already has the results of the analysis before the consultation
or can give advice to adjust the dose over the telephone.
In conclusion, an oral fluidmethod of analysis was successfully
developed and clinically validated for fluconazole in hospitalized
children and infants and can be a noninvasive, painless alternative
to perform TDM of fluconazole when blood sampling is not pos-
sible or desirable.
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